Ireland
--:--IST
Recruiting Not applicable

Strength and Dual-Task on Sarcopenia in People With Parkinson's Disease

NCT07907302 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2027-01-11
Last updated
2026-10-30

Condition(s) studied

PARKINSON DISEASE (Disorder)Parkinsonism or Parkinson's Disease Nos

Investigational drug(s) / intervention(s)

Nutricional Education and General Exercise GuidelinesProgressive Resistance Training With Cognitive Dual-Task TrainingProgressive Resistance Training With Cognitive Dual-Task and Inestability Training

Nutricional Education and General Exercise Guidelines: Participants will receive standardized nutritional education and general physical exercise guidelines through a structured information booklet. An initial face-to-face session will be conducted to explain the educational materials and recommendations. A second face-to-face follow-up session will be held midway through the 12-week intervention period to answer questions, reinforce the recommendations, and review adherence to the proposed nutritional and exercise guidelines. No structured strength training or supervised exercise sessions will be provided as part of this intervention.

Progressive Resistance Training With Cognitive Dual-Task Training: Participants will receive standardized nutritional education and complete a 12-week supervised progressive resistance training program combined with cognitive dual-task training. Training will be performed twice weekly and will target the lower limbs, upper limbs, and trunk using dumbbells, resistance bands, weights, and bodyweight exercises. Training intensity will be individually adjusted and progressively increased toward 60%-90% of one-repetition maximum (1-RM). Training load will be periodically adjusted according to participant progression. Cognitive tasks will be performed simultaneously with physical exercises to address cognitive-motor interference.

Progressive Resistance Training With Cognitive Dual-Task and Inestability Training: Participants will receive standardized nutritional education and complete a 12-week supervised progressive resistance training program combined with cognitive dual-task training and instability components. Training will be performed twice weekly and will target the lower limbs, upper limbs, and trunk. The same relative strength-training intensity and load principles as the PRT intervention will be applied. Additional instability and postural control demands will be incorporated through unstable surfaces and other postural challenges. Training intensity and complexity will be individually adapted according to functional and cognitive status.

Study summary

Parkinson´s disease and parkinsonian syndromes are associated with progressive motor and non-motor impairments that may compromise functional independence and quality of life. Sarcopenia, characterized by reduced muscle strength, muscle mass, and physical performance, is highly prevalent in these populations and may contribute to an increased risk of falls, frailty, and disability.

This prospective, parallel-group, three-arm randomized controlled trial aims to compare the effects of three levels of physiotherapy intervention on sarcopenia-related parameters and physical function in adults with Parkinson´s disease or parkinsonian syndromes.

The Education Group will receive standarized nutritional education and general physical exercise recommendations through structed educational materials, without supervised exercise training. The Progressive Resistance Training (PRT) Group will receive standarized nutritional education and participate in supervised progressive resistance trained combined with cognitive dual-task exercises. The PRT plus Instability Group will receive the same nutritional education, progressive resistance training, and cognitive dual-task training, with additional instability and postural control components. Participants in the two supervised exercise groups will complete two physiotherapy sessions per week for 12 weeks.

Assessments will be conducted at baseline (T0), immediately after the 12-week intervention (T1), and four weeks after completion of the intervention (T2). Outcomes will include clinical and functional status, muscle strength, body composition and other sarcopenia-related measures, physical performance, nutritional status, neurocognitive status, number of falls, and Parkinson's disease-related clinical characteristics.

The study will evaluate the effects of supervised progressive resistance training compared with an educational intervention and will explore whether adding instability and postural control demands to progressive resistance training provides additional effects on physical function, sarcopenia-related outcomes, and fall-related functional risk in people with Parkinson's disease and parkinsonian syndromes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * Clinical diagnosis of Parkinson's disease or parkinsonism confirmed by a neurologist. * Hoehn and Yahr stage 1-3. * Age ≥18 years. * Stable antiparkinsonian drug treatment for at least the previous 4 weeks. * Ability to ambulate independently, with or without assistive devices. * Ability to understand and follow basic safety instructions. Exclusion Criteria: * Severe or uncontrolled additional pathology. * Other neurological diseases that interfere with the assessment. * Recent fractures. * Severe dyskinesias or unpredictable motor fluctuations that compromise safety. * Any medical condition that contraindicates supervised physical exercise

Primary outcome measure(s)

  • Handgrip Strength — Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2).
    Handgrip strength will be assessed using handgrip dynamometry as a measure of muscle strength within the EWGSOP2 sarcopenia assessment framework. Higher values indicate greater muscle strength.
  • Physical Performance - Short Physical Performance Battery (SPPB) — Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2).
    Physical performance will be assessed using the Short Physical Performance Battery (SPPB), which evaluates balance, gait speed, and lower-limb functional performance. The total score ranges from 0 to 12 points, with higher scores indicating better physical performance.
  • Body Composition -Body fat (%) — Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2).
    It will be assessed assessed using bioelectrical impedance analysis (BIA) , measured in %.
  • Body Composition -Body fat (kg) — Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2).
    It will be assessed assessed using bioelectrical impedance analysis (BIA), measured in kg.
  • Body Composition -Lean mass (kg) — Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2).
    It will be assessed assessed using bioelectrical impedance analysis (BIA) , measured in kg.
  • Body Composition -Lean mass (%) — Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2).
    It will be assessed assessed using bioelectrical impedance analysis (BIA) , measured in %.
  • Body Composition -body water(%) — Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2).
    It will be assessed assessed using bioelectrical impedance analysis (BIA) , measured in %.
  • Body Composition -body water(kg) — Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2).
    It will be assessed assessed using bioelectrical impedance analysis (BIA) , measured in kg.

Trial sites (1)

FacilityCityRegionStatus
Clínica NYR Valencia Valencia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07907302 on ClinicalTrials.gov ↗ ← All trials in Spain